Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Edaravone is a Therapeutic Candidate for Doxorubicin-Induced Cardiomyopathy by Activating the Nrf2 Pathway.
Pharmacol Res Perspect
February 2025
Department of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Doxorubicin (DOXO) has long been used clinically and remains a key drug in cancer therapy. DOXO-induced cardiomyopathy (DICM) is a chronic and fatal complication that severely limits the use of DOXO. However, there are very few therapeutic agents for DICM, and there is an urgent need to identify those that can be used for a larger number of patients.
View Article and Find Full Text PDFNeuropeptides in the hypothalamus.
Vitam Horm
January 2025
Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla and León (INCYL), University of Salamanca, Salamanca, Spain; Grupo GIR USAL-BMD (Bases Moleculares del Desarrollo), University of Salamanca, Salamanca, Spain.
The hypothalamus is one of the most complex region in the central nervous system regarding neuroanatomy, neurochemical content, neuropeptide/classical neurotransmitter interactions, physiological actions, and pathophysiology. Hypothalamic neuropeptides have been involved in a large plethora of mechanisms related with obesity, anxiety, feeding, energy metabolism, defensive behavior, mood, and reproduction. The therapeutic potential of these findings is enormous but the physiological complexity occurring in the hypothalamus is huge due in part to the interactions between numerous neuropeptides as well as between neuropeptides and other neuroactive substances.
View Article and Find Full Text PDFAssessing diapocynin's different effects on osteosarcoma and breast cancer cells: An in vitro study.
Tissue Cell
January 2025
Department of Biological Science, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil. Electronic address:
Osteosarcoma is the most common primary bone cancer, accounting for approximately 5 % of new cancer cases globally. In contrast, breast cancer remains the most prevalent malignancy and a leading cause of cancer-related mortality among women. Given the limitations of current therapies, novel treatment strategies are urgently needed.
View Article and Find Full Text PDFDeployment and transcriptional evaluation of nitisinone, an FDA-approved drug, to control bed bugs.
Pest Manag Sci
January 2025
Department of Biological Sciences, University of Cincinnati, Cincinnati, OH, USA.
Background: Bed bugs are blood-feeders that rapidly proliferate into large indoor infestations. Their bites can cause allergies, secondary infections and psychological stress, among other problems. Although several tactics for their management have been used, bed bugs continue to spread worldwide wherever humans reside.
View Article and Find Full Text PDFPotential of carbon micro/nanofibers derived from lignocellulose biomass valorisation for CO adsorption: A review on decarbonization biotechnology for climate change solutions.
Int J Biol Macromol
January 2025
Desalination Technology Institute, King Abdulaziz City for Science and Technology, Riyadh 12354, Saudi Arabia.
Biomass, as a source of lignocellulose, can be valorized into carbon micro/nanofibers for adsorbing greenhouse gas (GHGs) emissions, especially CO. This article is derived from systematic evidence evaluation of published studies, presenting new, innovative, and systemic approaches to lignocellulose-based carbon micro/nanofiber studies. The review covers a general overview of carbon micro/nanofiber studies, mapping chronicles of the studies, carbon micro/nanofiber types for CO uptake, carbon micro/nanofibers fabrication and characterization, obtained carbonaceous material activation and performances, regulatory frameworks, and sustainability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!